XML 28 R19.htm IDEA: XBRL DOCUMENT v3.25.3

Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Information Related to Statement of Operations

Schedule of Segment Information Related to Statement of Operations

		2025				2024				2025				2024
		Nine months ended September 30,								Three months ended September 30,
		2025				2024				2025				2024
Revenue		$	1,049,125			$	1,157,380			$	359,444			$	354,408
Operating Expenses:
Employee compensation			834,855				746,582				235,785				230,896
Professional fees			185,039				151,614				52,382				37,500
Directors fees and expenses			227,254				121,306				148				-
Marketing and investor relations			187,467				125,187				109,201				27,946
Insurance**			131,079				144,534				39,535				46,151
Occupancy costs			63,229				43,457				21,097				13,306
Credit loss expense			124,253				25,001				-				25,001
Patent costs			58,944				54,535				31,826				20,339
Stock listing fees			52,500				49,125				17,500				16,375
Legal fees			1,070				33,062				-				5,087
Depreciation and amortization			8,603				11,211				2,879				3,789
Other operating expenses*			59,748				59,538				11,289				28,476
Operating expenses			1,934,041				1,565,152				521,642				454,866
Research and Development Expenses
Employee compensation			125,743				115,561				35,100				35,511
Insurance**			128,302				140,973				38,668				45,174
Occupancy costs			192,374				133,883				64,578				43,437
Depreciation and amortization			676				8,371				233				2,841
Other research and development costs			26,614				11,029				3,167				4,283
Research and development expenses			473,709				409,817				141,746				131,246
Operating Loss		$	(1,358,625	)		$	(817,589	)		$	(303,944	)		$	(231,704	)

*	Other operating expenses and other research and development expenses consist principally of miscellaneous expenses, each of which is under the Company’s threshold to be separately presented as a significant expense.
**	Insurance includes all coverage including property, liability, directors’ and officers’ and employees’ medical.

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration